BR112017000898A2 - oritavancina de alta pureza e método de produção da mesma - Google Patents

oritavancina de alta pureza e método de produção da mesma

Info

Publication number
BR112017000898A2
BR112017000898A2 BR112017000898A BR112017000898A BR112017000898A2 BR 112017000898 A2 BR112017000898 A2 BR 112017000898A2 BR 112017000898 A BR112017000898 A BR 112017000898A BR 112017000898 A BR112017000898 A BR 112017000898A BR 112017000898 A2 BR112017000898 A2 BR 112017000898A2
Authority
BR
Brazil
Prior art keywords
high purity
production method
oritavancin
purity oritavancin
preparations
Prior art date
Application number
BR112017000898A
Other languages
English (en)
Inventor
Rafai Far Adel
M Knable Carl
M Reamer Douglas
Krishna Gopal
J Petzel James
J Pruyne Julie
Ding Min
R Chemburkar Sanjay
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of BR112017000898A2 publication Critical patent/BR112017000898A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

a presente invenção se refere a preparações de substâncias medicamentosas de oritavancina tendo uma elevada pureza, assim como composições farmacêuticas as quais compreendem as preparações de substâncias medicamentosas de oritavancina referidas, bem como produtos medicamentosos ou formas de dosagem compreendendo as composições farmacêuticas referidas.
BR112017000898A 2014-07-17 2015-07-16 oritavancina de alta pureza e método de produção da mesma BR112017000898A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025737P 2014-07-17 2014-07-17
PCT/US2015/040736 WO2016011245A1 (en) 2014-07-17 2015-07-16 High purity oritavancin and method of producing same

Publications (1)

Publication Number Publication Date
BR112017000898A2 true BR112017000898A2 (pt) 2017-11-21

Family

ID=55073658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000898A BR112017000898A2 (pt) 2014-07-17 2015-07-16 oritavancina de alta pureza e método de produção da mesma

Country Status (12)

Country Link
US (3) US9649352B2 (pt)
EP (1) EP3169345A4 (pt)
JP (1) JP6712991B2 (pt)
CN (1) CN107206050A (pt)
AU (1) AU2015289602B2 (pt)
BR (1) BR112017000898A2 (pt)
CA (1) CA2955256C (pt)
EA (1) EA201700019A1 (pt)
HK (1) HK1244447A1 (pt)
MX (1) MX2017000676A (pt)
NZ (1) NZ728401A (pt)
WO (1) WO2016011245A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107793472A (zh) * 2016-09-07 2018-03-13 浙江海正药业股份有限公司 奥利万星二磷酸盐的晶型及其制备方法和用途
CN106928323B (zh) * 2017-03-02 2021-08-20 重庆乾泰生物医药有限公司 一种高纯度奥利万星关键中间体a82846b的制备方法
CN109053864B (zh) * 2018-07-10 2021-08-24 丽珠集团新北江制药股份有限公司 一种制备奥利万星的方法
CN109053865B (zh) * 2018-07-20 2021-04-13 丽珠集团新北江制药股份有限公司 一种羧基保护制备奥利万星的方法
CN109811024B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 发酵制备奥利万星中间体的方法
CN109811023B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 A82846b的发酵制备方法
CN109762860B (zh) * 2019-04-02 2021-10-01 博瑞生物医药泰兴市有限公司 一种碱降解液
CN110824079B (zh) * 2019-11-27 2021-04-13 苏州赛分科技有限公司 特拉万星的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18377A (en) * 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US4845194A (en) 1987-02-27 1989-07-04 Eli Lilly And Company Glycopeptide recovery process
NZ236393A (en) * 1989-12-13 1992-05-26 Lilly Co Eli N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
RU2145609C1 (ru) * 1994-01-28 2000-02-20 Эли Лилли Энд Компани Производные гликопептида или их соли, способ получения, фармацевтическая композиция
ID18900A (id) * 1996-11-21 1998-05-20 Lilly Co Eli Alkilasi menurun dari gliko peptida anti biotik
US5939382A (en) * 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
US6355843B1 (en) 1998-05-05 2002-03-12 Eli Lilly And Company Purification of carboxaldehyde
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
HUE041133T2 (hu) * 2002-11-18 2019-05-28 Vicuron Pharmaceuticals Llc Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2009126502A2 (en) 2008-04-08 2009-10-15 Targanta Therapeutics Corp. Methods of inhibiting and treating biofilms using glycopeptide antibiotics
EA020490B1 (ru) 2008-08-30 2014-11-28 Тарганта Терапьютикс Корп. Способ лечения бактериальной инфекции
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
WO2011019839A2 (en) * 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility

Also Published As

Publication number Publication date
CA2955256A1 (en) 2016-01-21
HK1244447A1 (zh) 2018-08-10
US9649352B2 (en) 2017-05-16
US20160015772A1 (en) 2016-01-21
EP3169345A1 (en) 2017-05-24
CN107206050A (zh) 2017-09-26
EA201700019A1 (ru) 2017-07-31
US10328118B2 (en) 2019-06-25
MX2017000676A (es) 2018-01-11
AU2015289602A1 (en) 2017-02-09
EP3169345A4 (en) 2018-01-17
JP2017521443A (ja) 2017-08-03
US10864249B2 (en) 2020-12-15
NZ728401A (en) 2020-08-28
AU2015289602B2 (en) 2020-06-25
CA2955256C (en) 2023-02-14
US20170157206A1 (en) 2017-06-08
JP6712991B2 (ja) 2020-06-24
US20190290723A1 (en) 2019-09-26
WO2016011245A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
BR112017012005A2 (pt) compostos orgânicos
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
NZ740062A (en) Improved process for producing fucoxanthin and/or polysaccharides from microalgae
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
AU2015303724B2 (en) Quinazoline derivative
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
MD4763C1 (ro) Compoziţie farmaceutică

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THE MEDICINES COMPANY (US) , ABBVIE INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]